Pfizer Ready To Settle Neurontin Promotion Case; Reserves $427 Mil.
Executive Summary
Pfizer expects to pay over $400 mil. to resolve the Boston U.S. Attorney's investigation of Neurontin promotions
You may also be interested in...
Vioxx Liability Exposure May Exceed 5-Year Product Sales Of $12 Bil.
Merck's liability exposure from Vioxx could exceed total sales of the COX-2 inhibitor from its five years on the market
Vioxx Liability Exposure May Exceed 5-Year Product Sales Of $12 Bil.
Merck's liability exposure from Vioxx could exceed total sales of the COX-2 inhibitor from its five years on the market
Merck After Vioxx: No Merger, But No Big Near-Term Launches
Following Merck's decision to withdraw Vioxx from the market, an FDA approval of the follow-on COX-2 inhibitor Arcoxia is likely to be delayed